Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Tacrolimus binds to FKBP12 protein and inhibits calcineurin, blocking T-cell activation and suppressing inflammatory cytokines (IL-2, IL-4, IFN-γ) in skin tissue. This targeted immunosuppression reduces inflammation without the skin-thinning effects of topical corticosteroids.
Commercial tacrolimus ointment (Protopic) is available only at 0.03% and 0.1% in ointment base, which many patients find greasy. Compounding allows cream bases, alternative concentrations, and combination with other actives.
Compare up to 7,500 pharmacies across the USA.
Tacrolimus (FK506) is a macrolide immunosuppressant derived from Streptomyces tsukubaensis. Topically, it is a first-line non-steroidal treatment for moderate-to-severe atopic dermatitis, particularly valuable for facial and eyelid eczema where steroid use is limited by side effects.
As a steroid-sparing agent, tacrolimus is crucial for long-term eczema management. Compounded cream formulations are preferred by many patients over the commercial ointment base, which can feel greasy and occlusive.
Calcineurin Inhibition
Tacrolimus binds to the cytosolic protein FKBP12, and the tacrolimus-FKBP12 complex inhibits calcineurin — a phosphatase that activates the transcription factor NFAT. This blocks T-cell production of inflammatory cytokines including IL-2, IL-4, IL-5, IFN-γ, and TNF-α.
Selective Immunosuppression
Unlike topical corticosteroids which broadly suppress multiple cell types and affect collagen synthesis, tacrolimus selectively targets T-lymphocyte activation in the skin — providing anti-inflammatory efficacy without epidermal atrophy, telangiectasia, or HPA axis suppression.
Atopic dermatitis (eczema), facial and periorbital eczema, psoriasis (off-label), vitiligo (to halt immune-mediated progression), contact dermatitis, seborrheic dermatitis
Vitiligo (combined with phototherapy), oral lichen planus, genital lichen sclerosus (off-label alternative to corticosteroids), periorificial dermatitis, lupus-related skin manifestations, inverse psoriasis (skin fold areas where steroid atrophy is a concern)
Standard: 0.03–0.1% applied twice daily to affected areas
Duration: Until skin clears, then taper to maintenance frequency
Maintenance: 2–3x weekly for chronic conditions
Children ≤15 years: Maximum 0.03% concentration per labeling
Begin with twice-daily application to affected areas. Once skin is clear, taper to maintenance therapy — typically 2–3x weekly on previously affected areas. Proactive maintenance therapy significantly reduces flare frequency. Initial burning/stinging typically improves substantially within 1–2 weeks of regular use.
Topical Cream (0.03%, 0.1%) — more comfortable base than commercial ointment; better for facial and fold areas; preferred by most patients for daily use
Topical Ointment (custom base) — alternative base for drier skin types or patients preferring occlusive coverage
Custom Concentrations — intermediate concentrations (e.g., 0.05%) can be compounded for patients who respond to 0.03% but need slightly more potency than commercial options allow
Transient burning or stinging on application (typically resolves after first week). Increased herpes simplex (HSV) infection risk during flares. FDA black box warning: theoretical risk of lymphoma and skin malignancy (clinical evidence inconclusive). Avoid prolonged UV exposure during treatment.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
